GTx,Inc. (NASDAQ:GTXI) Files An 8-K Entry into a Material Definitive Agreement

GTx,Inc. (NASDAQ:GTXI) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement.

Story continues below

On September25, 2017, GTx,Inc. (the “Company”) entered into a definitive securities purchase agreement (the “Purchase Agreement”) with certain purchasers identified on the pagesthereto (the “Purchasers”) to which the Company agreed to sell an aggregate of 5,483,320 immediately separable units (the “Units”), comprised of an aggregate of 5,483,320 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and warrants (the “Warrants”) to purchase up to a maximum of 3,289,988 additional shares of Common Stock (the “Warrant Shares”), for an aggregate purchase price of approximately $48.5 million (the “Private Placement”). The per Unit purchase price for a share of Common Stock and a Warrant to purchase 0.6 of a share of Common Stock was $8.845. On September29, 2017 (the “Closing Date”), the Company completed the sale of the Units and separately issued to the Purchasers the Shares and the Warrants. The Purchasers consisted solely of accredited investors that included certain institutional and existing stockholders, including J.R. Hyde III who serves on the Company’s board of directors.

The Warrants issued to the Purchasers on the Closing Date have a per share exercise price of $9.02, subject to adjustment as provided in the Warrants, and are immediately exercisable at any time and from time to time through and including September29, 2022. The exercise price is payable in cash or may be satisfied through a cashless exercise, at the option of the Warrant holder. Each Warrant also provides that the holder thereof may not exercise such Warrant for a number of shares of Common Stock in excess of that number of shares that, upon giving effect to such exercise, would cause the Warrant holder (together with its affiliates) to beneficially own more than a specified percentage of the Common Stock and/or the combined voting power of the Company’s outstanding voting securities, as the case may be.

to the Purchase Agreement, the Company agreed to file as many registration statements with the Securities and Exchange Commission (the “SEC”) as may be necessary to cover the resale of the Shares and the Warrant Shares by the Purchasers, to use its reasonable best efforts to have all such registration statements declared effective as required by and within the timeframes set forth in the Purchase Agreement, and to keep such registration statements effective for up to two years following the Closing Date. In the event that such registration statements are not filed or declared effective within the timeframes set forth in the Purchase Agreement, or any such effective registration statements subsequently become unavailable, the Company would, subject to certain limited exceptions, be required to pay liquidated damages equal to 1.0% of the aggregate Unit purchase price per month for each default (up to a maximum of 10% of such aggregate Unit purchase price). The Company will bear all expenses of such registration of the resale of the Shares and the Warrant Shares, including the reasonable fees and disbursements, not to exceed $15,000 in the aggregate, of one counsel for the Purchasers.

The Purchase Agreement contains customary representations, warranties and agreements by the Company, indemnification obligations of the Company and the Purchasers, including for liabilities under the Securities Act of 1933, as amended (the “Securities Act”), and other obligations of the parties. The representations, warranties and covenants contained in the Purchase Agreement were made only for purposes of such Purchase Agreement and are made as of specific dates; are solely for the benefit of the parties (except as specifically set forth therein); may be subject to qualifications and limitations agreed upon by the parties in connection with negotiating the terms of the Purchase Agreement, including being qualified by confidential disclosures made for the purpose of allocating contractual risk between the parties, instead of establishing matters as facts; and may be subject to standards of materiality and knowledge applicable to the contracting parties that differ from those applicable to the investors generally. Investors should not rely on the representations, warranties and covenants or any description thereof as characterizations of the actual state of facts or condition of the Company.

The securities issued by the Company to the Purchase Agreement and to be issued upon exercise of the Warrants have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. The Company relied and will rely on the private placement exemption from registration provided by Section4(a)(2)of the Securities Act and by Rule506 of Registration D, promulgated by the SEC, and on similar exemptions under applicable state laws. The Company will file a FormD in accordance with the requirements of Regulation D.

The foregoing descriptions of the Purchase Agreement and the Warrants are only brief summaries of such agreements and documents, do not purport to be complete and are qualified in their entirety by reference to the Purchase Agreement (and the form of Warrant attached thereto) filed as Exhibit10.1 to this Current Report on Form8-K and incorporated by reference herein.

Item 3.02. Unregistered Sales of Equity Securities.

The disclosures set forth in Item 1.01 above are incorporated herein for this Item 3.02.

Item 8.01. Other Events.

On September26, 2017, the Company issued a press release titled “GTx Announces $48.5 Million Private Placement” and on September29, 2017, the Company issued a press release titled “GTx Announces Closing of $48.5 Million Private Placement.” Copies of the press releases are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.


GTX INC /DE/ Exhibit
EX-10.1 2 a17-22639_1ex10d1.htm EX-10.1 Exhibit 10.1   SECURITIES PURCHASE AGREEMENT   This Securities Purchase Agreement (this “Agreement”) is dated as of September 25,…
To view the full exhibit click here

About GTx,Inc. (NASDAQ:GTXI)

GTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs). Its lead product candidate, enobosarm (GTx-024), had been evaluated in over 24 completed or ongoing clinical trials, including in approximately six Phase II and two Phase III clinical trials. The Company is also engaged in the development of GTx-758 (Capesaris), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with metastatic and high-risk non-metastatic castration resistant prostate cancer (CRPC). Its product candidate, Enobosarm, for the treatment of women with advanced androgen receptor (AR) positive triple-negative breast cancer (TNBC), is in Phase II clinical development-stage.

An ad to help with our costs